BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 24634399)

  • 21. Tandem stem cell rescue as consolidation therapy for high-risk neuroblastoma.
    Qayed M; Chiang KY; Ricketts R; Alazraki A; Tahvildari A; Haight A; George B; Esiashvili N; Katzenstein HM
    Pediatr Blood Cancer; 2012 Mar; 58(3):448-52. PubMed ID: 21538822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment with topotecan plus cyclophosphamide in children with first relapse of neuroblastoma.
    Ashraf K; Shaikh F; Gibson P; Baruchel S; Irwin MS
    Pediatr Blood Cancer; 2013 Oct; 60(10):1636-41. PubMed ID: 23650219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Long-term effect of high dose chemotherapy combined with stem cell transplantation on stage IV neuroblastoma in children].
    Tang SQ; Huang DS; Wang JW; Feng C; Yang G
    Zhongguo Dang Dai Er Ke Za Zhi; 2006 Apr; 8(2):93-6. PubMed ID: 16613697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Second solid malignancies among children, adolescents, and young adults diagnosed with malignant bone tumors after 1976: follow-up of a Children's Oncology Group cohort.
    Goldsby R; Burke C; Nagarajan R; Zhou T; Chen Z; Marina N; Friedman D; Neglia J; Chuba P; Bhatia S
    Cancer; 2008 Nov; 113(9):2597-604. PubMed ID: 18823030
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation.
    Forrest DL; Hogge DE; Nevill TJ; Nantel SH; Barnett MJ; Shepherd JD; Sutherland HJ; Toze CL; Smith CA; Lavoie JC; Song KW; Voss NJ; Gascoyne RD; Connors JM
    J Clin Oncol; 2005 Nov; 23(31):7994-8002. PubMed ID: 16204014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of poor-risk neuroblastoma patients with high-dose chemotherapy and autologous peripheral stem cell rescue.
    Cohn SL; Moss TJ; Hoover M; Katzenstein HM; Haut PR; Morgan ER; Green AA; Kletzel M
    Bone Marrow Transplant; 1997 Oct; 20(7):543-51. PubMed ID: 9337055
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine.
    Huibregtse KE; Vo KT; DuBois SG; Fetzko S; Neuhaus J; Batra V; Maris JM; Weiss B; Marachelian A; Yanik GA; Matthay KK
    Eur J Cancer; 2016 Oct; 66():144-52. PubMed ID: 27573428
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Second neoplasms after megavoltage radiation for pediatric tumors.
    Gold DG; Neglia JP; Dusenbery KE
    Cancer; 2003 May; 97(10):2588-96. PubMed ID: 12733158
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II Study.
    Kletzel M; Katzenstein HM; Haut PR; Yu AL; Morgan E; Reynolds M; Geissler G; Marymount MH; Liu D; Kalapurakal JA; Shore RM; Bardo DM; Schmoldt J; Rademaker AW; Cohn SL
    J Clin Oncol; 2002 May; 20(9):2284-92. PubMed ID: 11980999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma.
    Brown JR; Yeckes H; Friedberg JW; Neuberg D; Kim H; Nadler LM; Freedman AS
    J Clin Oncol; 2005 Apr; 23(10):2208-14. PubMed ID: 15753460
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allogeneic hematopoietic stem cell transplantation for pediatric patients with treatment-related myelodysplastic syndrome or acute myelogenous leukemia.
    Kobos R; Steinherz PG; Kernan NA; Prockop SE; Scaradavou A; Small TN; Shukla N; Khalaf R; O'Reilly RJ; Boulad F
    Biol Blood Marrow Transplant; 2012 Mar; 18(3):473-80. PubMed ID: 22079789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Second malignant neoplasms following chemoreduction with carboplatin, etoposide, and vincristine in 245 patients with intraocular retinoblastoma.
    Turaka K; Shields CL; Meadows AT; Leahey A
    Pediatr Blood Cancer; 2012 Jul; 59(1):121-5. PubMed ID: 21826785
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resource utilization and toxicities after single versus tandem autologous stem cell rescue in high-risk neuroblastoma using a national administrative database.
    Desai AV; Li Y; Getz K; Seif AE; Fisher B; Huang V; Aplenc R; Bagatell R
    Pediatr Blood Cancer; 2018 Dec; 65(12):e27372. PubMed ID: 30070014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
    Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy.
    Valteau-Couanet D; Le Deley MC; Bergeron C; Ducassou S; Michon J; Rubie H; Le Teuff G; Coze C; Plantaz D; Sirvent N; Bouzy J; Chastagner P; Hartmann O
    Pediatr Blood Cancer; 2014 Jun; 61(6):977-81. PubMed ID: 23970413
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term adverse effects on dentition in children with poor-risk neuroblastoma treated with high-dose chemotherapy and autologous stem cell transplantation with or without total body irradiation.
    Hölttä P; Alaluusua S; Saarinen-Pihkala UM; Wolf J; Nyström M; Hovi L
    Bone Marrow Transplant; 2002 Jan; 29(2):121-7. PubMed ID: 11850706
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel intensive induction therapy for high-risk neuroblastoma utilizing sequential peripheral blood stem cell collection and infusion as hematopoietic support.
    Pradhan KR; Johnson CS; Vik TA; Sender LS; Kreissman SG
    Pediatr Blood Cancer; 2006 Jun; 46(7):793-802. PubMed ID: 16206215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group.
    Ravindranath Y; Yeager AM; Chang MN; Steuber CP; Krischer J; Graham-Pole J; Carroll A; Inoue S; Camitta B; Weinstein HJ
    N Engl J Med; 1996 May; 334(22):1428-34. PubMed ID: 8618581
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk neuroblastoma patients.
    Molina B; Alonso L; Gonzalez-Vicent M; Andion M; Hernandez C; Lassaletta A; Cormenzana M; Lopez-Ibor B; Villa M; Molina J; Diaz MA
    Pediatr Hematol Oncol; 2011 Mar; 28(2):115-23. PubMed ID: 21299340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.